Omeros (OMER) Share-based Compensation (2010 - 2026)
Omeros (OMER) posted Share-based Compensation of $1.9 million for Q1 2026, up 9.0% sequentially from $1.7 million in Q4 2025, and down 22.99% YoY from $2.5 million in Q1 2025.
Omeros (OMER) Share-based Compensation (2010 - 2026) Analysis & Trends
Omeros has reported Share-based Compensation for 17 years, with the latest figure at $1.9 million in Q1 2026.
- Quarterly Share-based Compensation fell 22.99% year-over-year to $1.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.5 million (down 14.37% YoY) and the FY2025 annual result came in at $12.1 million, down 3.2% from the prior year.
- Share-based Compensation rose to $1.9 million in Q1 2026 per OMER's latest filing, from $1.7 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $3.9 million in Q1 2022 and troughed at $856000.0 in Q3 2025.
- A 5-year average of $2.5 million and a median of $2.7 million in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation slumped 67.14% in 2024, then climbed 21.54% in 2025.
- Over 5 years, Share-based Compensation stood at $3.3 million in 2022, then dropped by 17.56% to $2.7 million in 2023, then decreased by 9.85% to $2.4 million in 2024, then declined by 28.57% to $1.7 million in 2025, then increased by 9.0% to $1.9 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $1.9 million, $1.7 million, and $856000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Omeros | 1.24 Bn | 1.24 Bn | 27.73 Mn | 1.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.62 Mn |
| Jun 30, 2026 | 1.62 Mn |
| Mar 31, 2026 | 1.89 Mn |
| Mar 31, 2026 | 1.89 Mn |
| Dec 31, 2025 | 1.73 Mn |
| Dec 31, 2025 | 1.73 Mn |
| Sep 30, 2025 | 856,000.00 |
| Sep 30, 2025 | 856,000.00 |
| Jun 30, 2025 | 2.07 Mn |
| Jun 30, 2025 | 2.07 Mn |
| Mar 31, 2025 | 2.45 Mn |
| Mar 31, 2025 | 2.45 Mn |
| Dec 31, 2024 | 2.43 Mn |
| Dec 31, 2024 | 2.43 Mn |
| Sep 30, 2024 | 1.06 Mn |
| Sep 30, 2024 | 1.06 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Mar 31, 2024 | 2.66 Mn |
| Mar 31, 2024 | 2.66 Mn |